Pancreatic Cancer Research

ResearcherUniversity of Wisconsin–MadisonActive in the last 2 years

Dawei Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4072-0075; OpenAlex author ID A5016526230. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 1 paper

Papers 9

  1. Preclinical Development and Comparison of [99mTc]Tc/[177Lu]Lu-Labeled Anti-Trop2 Fc-Fused Nanobodies as Pancreatic Cancer Theranostics. Co-author DOI 10.1021/acs.molpharmaceut.5c01039↗
  2. Construction of a combined prognostic model for pancreatic ductal adenocarcinoma based on deep learning and digital pathology images. Co-author DOI 10.1186/s12876-024-03469-4↗
  3. FAM53B promotes pancreatic ductal adenocarcinoma metastasis by regulating macrophage M2 polarization. Co-author DOI 10.4251/wjgo.v16.i4.1479↗
  4. ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer. Co-author DOI 10.1007/s00259-021-05563-1↗
  5. ImmunoPET/NIRF/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00259-021-05216-3↗
  6. Low Serum miR-607 Level as a Potential Diagnostic and Prognostic Biomarker in Patients of Pancreatic Ductal Adenocarcinoma: A Preliminary Study. Co-author DOI 10.1155/2021/8882129↗
  7. 86/90Y-Labeled Monoclonal Antibody Targeting Tissue Factor for Pancreatic Cancer Theranostics. Co-author DOI 10.1021/acs.molpharmaceut.0c00127↗
  8. Functional polymorphisms in LncRNA HOTAIR contribute to susceptibility of pancreatic cancer. Co-author DOI 10.1186/s12935-019-0761-x↗
  9. Gain of microRNA-103 triggers metastatic behavior by targeting ubiquitin specific peptidase 10 in pancreatic cancer. Last author PMID 31933936↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Weibo Cai · 3 shared papers, 2020–2022 · strength 0.39
  2. Min Cai · 3 shared papers, 2019–2021 · strength 0.39
  3. Miao Li · 2 shared papers, 2021–2022 · strength 0.28
  4. Weiyu Chen · 2 shared papers, 2021–2022 · strength 0.28
  5. Liu Xu · 2 shared papers, 2019–2021 · strength 0.27
  6. Kaixin Hu · 1 shared paper, 2024 · strength 0.24
  7. Xuanzeng Pei · 1 shared paper, 2024 · strength 0.24
  8. Huangbao Li · 1 shared paper, 2024 · strength 0.24
  9. Fengqing Zhao · 1 shared paper, 2024 · strength 0.24
  10. Yifan Lu · 1 shared paper, 2024 · strength 0.24
  11. Yongkang Gai · 1 shared paper, 2025 · strength 0.23
  12. Feng Yuan · 1 shared paper, 2025 · strength 0.23
  13. Xiaoli Lan · 1 shared paper, 2025 · strength 0.23
  14. Lan Shen · 2 shared papers, 2019 · strength 0.23
  15. Min Zhou · 1 shared paper, 2022 · strength 0.15
  16. Jie Zhang · 1 shared paper, 2019 · strength 0.11
  17. Dalong Ni · 1 shared paper, 2020 · strength 0.11
  18. Carolina A. Ferreira · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.